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Salmonella infection in humans can become chronic, which leads to low-grade persistent inflammation. These
chronic infections increase the risk of several gastrointestinal diseases, including cancer. Salmonella AvrA is a
multifunctional protein that influences eukaryotic cell pathways by regulating ubiquitination and acetylation. In an
animal model, we have demonstrated that infection with AvrA-expressing Salmonella induces beta-catenin signals
and enhances colonic tumorigenesis. Beta-catenin signaling is a key player in intestinal proliferation and
tumorigenesis. The relative contributions of AvrA-induced proliferation and inflammation on tumorigenesis,
however, are unknown. STAT3 is activated in chronically inflamed intestines in human inflammatory bowel
diseases and in colitis-associated colon cancer. In the current study, mice were colonized with Salmonella AvrA-
sufficient or AvrA-deficient bacterial strains. Then, inflammation-associated colon cancer was induced through the
use of azoxymethane/dextran sulfate sodium. We determined that AvrA-expressing bacteria activated the STAT3
pathway, which is predicted to enhance proliferation and promote tumorigenesis. Transcriptional activity of STAT3
and its target genes were upregulated by Salmonella expressing AvrA, thus promoting proliferation and intestinal
tumorigenesis. Our findings provide new insights regarding a STAT3-dependent mechanism by which the specific
bacterial product AvrA enhances the development of infection-associated colon cancer. These insights might
suggest future biomarkers to risk assessment and early detection of infection-related cancer.
Neoplasia (2016) 18, 307–316Address all correspondence to: Jun Sun, PhD, AGAF, Associate Professor, Division of
Gastroenterology and Hepatology, Department of Medicine, University of Illinois at
Chicago, 840 S Wood St, Room 704 CSB, Chicago, IL, 60612.
E-mail: junsun7@uic.edu
1Conflicts of Interest: The authors have no conflicts of Interest.
Received 18 March 2016; Accepted 7 April 2016
© 2016 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open
access article under theCCBY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1476-5586
http://dx.doi.org/10.1016/j.neo.2016.04.001Introduction
Accumulating evidence suggests that chronic infection and the
ensuing inflammation contribute to tumor initiation and tumor
progression [1,2]. Several studies have implicated colonic bacteria in
the pathogenesis of colon cancer. A recent study in mice showed that
adenomas cause barrier defects in the colonic epithelium allowing
microbial products to drive interleukin (IL)-23/IL-17–mediated
tumor growth [3]. Another study demonstrated that a human
colonic commensal bacterium promoted tumorigenesis via activation
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promote tumorigenesis by altering microbial composition and
inducing the expansion of microorganisms with genotoxic capabilities
[5]. Specifically, deletion of the polypetide synthase genotoxin from
Escherichia coli NC101 decreased tumor load and tumor invasion
in azoxymethane (AOM)-treated IL-10 knockout mice. These studies
have highlighted the essential roles of bacteria and/or their products in
colonic tumorigenesis.
Salmonella infection in humans can become chronic, which leads
to low-grade persistent inflammation [2]. These chronic infections
increase the risk of several gastrointestinal [6] diseases, including
chronic cholecystitis and gallbladder cancer [7,8]. Recently, Kato et al.
reported that antibody against Salmonella flagellin was higher in
colorectal cancer and precancer cases than controls in two distinct
populations in the United States and the Netherlands and that dietary
intake is the one of the mediating factors, suggesting a potential link of
Salmonella to colorectal cancer [9]. In animal models, Salmonella and its
derivatives have been observed invading transformed tissue more
efficiently than normal tissue [10,11]. Salmonella AvrA is a
multifunctional protein that influences eukaryotic cell pathways by
altering ubiquitination and acetylation of target proteins [12–18].
These posttranslational modifications modulate protein functions that
regulate inflammation, epithelial apoptosis, and proliferation [12–18].
We recently reported that AvrA acts as a deubiquitinase to stabilize
β-catenin. By suppressing β-catenin degradation, AvrA enhances
intestinal epithelial proliferation [17] and promotes tumorigenesis [19].
Chronic infections activate multiple signaling pathways which
contribute to inflammatory responses that promote tumor develop-
ment [20]. In fact, epidemiologic studies and randomized clinical
trials have provided strong evidence that use of aspirin and
nonsteroidal anti-inflammatory drugs reduces the risk of colorectal
cancer [21,22]. In prior studies, we showed that AvrA activates
β-catenin signaling, which is a key signal transduction event in
intestinal proliferation and tumorigenesis [19]. However, the relative
contributions of AvrA to proliferation and inflammation have not
been dissected. STAT3 is known to be activated in chronic inflamed
intestine in human inflammatory bowel diseases [23] and colitis-
associated colon cancer [24]. At early stages of infection, STAT3
activation promoted inflammation, whereas at later stages, sustained
STAT3 activation suppressed inflammatory responses and promoted
proliferation [24]. Hyperproliferation alone, however, is insufficient
to cause cancer, which requires both the initiation of mutagenic
events that trigger cellular transformation as well as an activated
microenvironment that supplies growth factors to support cellular
survival, proliferation, and angiogenesis. Because AvrA promotes
tumorigenesis and STAT3 is activated in tumor development, we
speculated that AvrA might activate STAT3 in colonic tumorigenesis.
In the current study, we aimed to assess the role of bacterial protein
AvrA in activating STAT3 in colon cancer development. We
hypothesized that the bacterial effector AvrA would activate the
STAT3 pathway to promote inflammation-associated colonic
tumorigenesis. In prior studies, we established a mouse colon cancer
model possessing Salmonella AvrA+ or AvrA− infection in the
gastrointestinal tract [25]. We initiated colonic epithelial cell
mutations with AOM and accelerated tumorigenesis with dextran
sulfate sodium (DSS). To determine the effects of AvrA, we infected
mice with bacterial strains expressing AvrA (parental PhoPc),
AvrA-deficient strains (AvrA−), or PhoPc AvrA− strains complemen-
ted with a plasmid encoding AvrA (PhoPc AvrA−/AvrA+), as wepreviously described [15–17,26,27]. PhoP-PhoQ is a two-component
regulatory system that controls the expression of over 40 genes essential
for Salmonella typhimurium virulence and survival within macrophages.
PhoPc is a PhoP-PhoQ constitutive mutation that increases the
expression of PhoP-activated genes and represses the synthesis of 20
proteins encoded by PhoP-repressed genes [28]. We found that AvrA
expression induced STAT3 activation and contributed to systemic and
colonic inflammation in infected mice. Our findings provide important
mechanistic insights into how a bacterial protein targets colonic
epithelial cells and contributes to the development of colon cancer.
Results
Local Cytokines Accumulate in the AvrA-Expressed Tumor
Our previous study showed the pathological changes associated with
chronic Salmonella infection and differences in tumor development
(adenoma versus carcinoma) and between AvrA− and AvrA+ AOM/
DSS experimental groups [19]. Many cytokines and chemokines are
produced by activated stromata and immune cells during chronic
inflammation in tumor development. These cytokines accumulate
locally and can be detected in the tissue [29]. We assessed several
lymphocyte markers in normal colon and colonic tumors (Figure 1A).
Levels of CD4, CD14, CD45, and CD3 significantly increased in
tumors. AvrA expression appeared to cause differential effects on these
markers but had no influence on CD11 (Figure 1B). These data indicate
that the local inflammation in the infected colon was associated with the
AvrA expression level in Salmonella.
The cancer microenvironment, reflecting a “wound that does not
heal,” recruits these populations of lymphocytes and macrophage cells
that are believed to contribute to cellular inflammation and tumor
promotion. Along with tumor necrosis factor (TNF-α), IL-6 is one of
the most commonly overexpressed cytokines in tumors. We
compared the IL-6 levels from these groups in both serum and
colonic mucosa (Figure 1C). Among the groups, we found that
Salmonella expressing PhoPc AvrA−/AvrA+ induced the highest IL-6
serum levels 45 weeks postinfection (Figure 1C, right panel). We
observed significant differences in IL-6 exclusively at 15 weeks
postinfection, whereas there were no significant differences at 1, 25,
and 45 weeks postinfection. Recently, IL-6 has been shown to play a
key role in maintaining the balance between the regulatory subclass of
T cells and Th17, effector T cells that produce IL-22, IL-17, IL-6,
TNFα, and proinflammatory chemokines [30]. We then tested the
IL-17 mRNA from the colonic mucosa. IL-17 expression was
significantly increased in the AvrA+ infected group (Figure 1D).
The STAT3 Pathway is Activated in the Salmonella Chronically
Infected Colon
STAT proteins, especially STAT3, are crucial for both the extrinsic
and the intrinsic pathways underlying cancer inflammation. IL-6
signals are mediated in part by activation of STAT3, a transcription
factor important in cancer development. Based on elevated cytokine
profiles in tissue and serum from infected mice, we presumed that the
STAT pathway might be activated by infection, which promotes
epithelial cancer. We confirmed this hypothesis by Western blotting
that showed consistently enhanced phosphorylated STAT3
(p-STAT3) and total STAT3 in colonocytes from PhoPCAvrA−/
AvrA+ infected mice (Figure 2A). There was no consistent change in
p-STAT1 in the infected mice (Figure 2A). We then examined the
distribution of STAT3 and p-STAT3 in colon from control and
infected mice (Figure 2B). We found significantly higher level of
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Figure 1. Inflammatory cytokines in chronically Salmonella-infected colon in mice. (A) Immunocyte infiltration in control and infected
colon cancer tissue by immunohistochemistry/immunofluorescence. (B) Quantitation of CD3-, CD4-, CD14-, CD45-, and CD11b-positive
cells in tumors or control mucosa/high-power field. *P b .05. (C) Serum IL-6 versus tissue levels of IL-6 45 weeks postinfection. n=4mice/
group. Serum IL-6 at indicated time points. (D) IL17 mRNA level was increased in the AvrA+-infected colon group. n = 4 mice/group.
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bacteria compared with those in uninfected mice (Figure 3C). The
quantitation of pSTAT3 was shown in Figure 3D. Nuclear pSTAT3
was increased in the “normal” colon tissue and tumors from mice
infected with Salmonella expressing AvrA.
AvrA Activates the Target Genes of STAT3 Signaling Pathway
in the Salmonella Infected Intestine
To assess the biological relevance of STAT3 signaling, we examined the
transcript levels of STAT.We did not find any changes of JAK2, STAT1,
and STAT3 at the mRNA level associated with AvrA in tumors andadjacent tissue by real-time polymerase chain reaction (PCR) (Figure 3A).
The STAT3 target genes,MMP7 and SOC3, were significantly increased,
which appeared to correlate with AvrA expression (Figure 3A). The
inflammatory cytokine INFγ was significantly enhanced in intestine
infected with the AvrA-deficient Salmonella, whereas mRNA expression
levels of MIP, IL-1β, ICAM, KC, and TNF-α did not appear to correlate
with AvrA expression in Salmonella (Figure 3A).
Activation of STAT3 Signaling Contributes to Proliferation
In normal-appearing tissue close to tumors and in tumors, we
found that the proliferation marker PCNA was significantly increased
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Figure 2. AvrA modulates STAT3 activation in AOM/DSS colonic tumors. (A, left panel) Representative Western blots of STAT1/3 and
p-STAT1/3 in control colons and tumors. (Right panel) Quantitation of nuclear pSAT3. (B and C) Immunostaining of p-STAT3 and STAT3 in
control colons and tumors from indicated groups. (D) Quantitation of nuclear p-STAT3 in normal and tumor tissue in the indicated groups.
Data are means ± SD. n = 5 mice/group. *P b .05, **P b .01.
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uninfected mice (Figure 3B). Interestingly, we also found that STAT3
activation was associated with phosphoactive c-Jun redistribution in
bacterially infected colons. Phosphoactive c-Jun was detected on colonic
crypt surfaces in mice infected with AvrA-expressing bacteria (Figure 3B).AvrA Activates the STAT-3 Signaling Pathway in the
Salmonella-Infected Colon Cancer Cells
To directly test the ability of AvrA to activate STAT3, we examined
colon cancer cells in cell cultures. We transfected human colonic
epithelial HCT116 cells with an AvrA plasmid and a lucifierase
AB
Figure 3. AvrA modulates target genes of the STAT3 pathway in AOM/DSS colonic tumors. (A) mRNA expression of target genes of the
STAT3 pathway in the AOM/DSS colon post–Salmonella infection. The total RNA from intestinal mucosa was extracted for a real-time PCR
45 weeks postinfection. Transcripts were assayed in triplicate. Data are means ± SD of n=5mice in each group. (B) The effect of AvrA on
intestinal proliferation post–Salmonella infection. PCNA and p-c-Jun staining in colon 45 weeks postinfection.
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significantly increased the STAT-3 transcriptional activity as assessed
by a STAT-3 promoter regulated-luciferase reporter (Figure 4A).
Moreover, purified AvrA protein induced total STAT3 protein and
p-STAT3 in a dose-dependent manner in human epithelial cells
(Figure 4B). By Immunostaining, we detected the nuclear STAT-3
induced by AvrA treatment (Figure 4C, red staining for STAT3).Taken together, our in vitro studies indicate that AvrA activates the
STAT3 signal pathway in Salmonella-infected colonocytes.
Discussion
In this study, we investigated the effects and mechanism of a chronic
infection with S. typhimurium in an AOM/DSS colon cancer model. We
discovered that Salmonella infection altered the distribution of multiple
AC
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Figure 4. Bacterial AvrA protein activates STAT3 signaling. (A) AvrA activates STAT3 promoters in HCT116 cells. HCT116 cells were
transiently co-transfected with a STAT3 reporter pGL3-STAT3 and a p-CMVAvrA, or pGL3-empty vector and p-CMVAvrA using a lipofectin
reagent. Each experiment was assayed in triplicate. * P b .05. (B) AvrA protein increases STAT3 and p-STAT3 in the HCT116 cells. Cells
were treated with purified AvrA protein for 30 minutes. Cell lysates were collected for the Western blots. (C) HCT116 cells were treated
with purified AvrA protein (20 μg/ml) for 1 hour. Immunofluorescence was performed using an anti-Stat3 antibody.
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STAT3 pathway and increased PCNA, a marker of proliferation in the
colon. This novel study provides critical insights regarding the
mechanisms of tumor promotion by AvrA involving colonic inflamma-
tion and proliferation. It is interesting to note that higher IL-6 levels in
prediagnostic plasma samples have been associated with increased risk of
subsequent colorectal cancer in both women and men mediated partly
through obesity [6,31]. Chronic STAT3 induces inflammation through
increasing IL-6 and, in turn, can be induced by inflammation.
Cancer is defined by six hallmarks, namely, uncontrolled growth,
evading growth suppressors, resisting cell death, enabling replicative
immortality, inducing angiogenesis, and activating invasion and
metastasis. Increasing evidence suggests that inflammation should be
included as a seventh feature on this list [2]. Many cytokines, angiogenic
factors, and chemokines are produced by activated stromata and immune
cells which accumulate during chronic inflammation [1]. These factors
exert profound survival and growth effects on resident (neoplastic)
epithelial cells, endothelial and stromal cells, as well as recruiting immune
cells. Our data indicate that Salmonella AvrA upregulates IL-6, which in
turn activates STAT3 and enhances proliferation. Solid tumors arecommonly infiltrated with immune cells that provide a milieu for
inflammation, which promotes tumor growth. We also found that
profiles of colonic mucosal and serum cytokines, although altered by
infection, are not closely correlated. It is known that STAT3 has a dual
and self-perpetuating role in inflammation. At early stages of infection,
STAT3 activation promoted inflammation; in contrast, at later stages,
sustained STAT3 activation suppressed inflammation and promoted
proliferation [24]. Our data for the changes of cytokines at different time
courses postinfection (Figure 1 and data not shown) reflect the different
roles of STAT3 in the progression of colon cancer. At early stages of
infection (1-15 weeks) in the AOM/DSS mice, STAT3 activation may
promote inflammation, whereas at later stages (45 weeks), sustained
STAT3 activation suppressed inflammatory responses and promoted
proliferation. As activators of transcription, the STATs upregulates the
expression of genes, thus being involved in all steps of tumor
development, including the induction and maintenance of an
inflammatory microenvironment, as well as the malignant transforma-
tion and progression due to the maintenance of a proinflammatory
state. Our data have shown that bacterial AvrA was able to regulate
STAT3 activation and function in the intestine.
Figure 5. The working model of STAT3 and AvrA interaction in chronic intestinal Salmonella infected in colon cancer. Salmonella effector
AvrA is secreted through the Salmonella Type Three Secretion System and persistently upregulates the STAT-3 signaling pathway.
Several STAT3 target genes were upregulated by Salmonella expressing AvrA. β-catenin–STAT3may co-regulate one another in a positive
feedback loop, thus promoting proliferation and intestinal tumorigenesis.
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tumorigenesis [32]. In the setting of acute Salmonella infections in
mice, AvrA exerts an anti-inflammatory effect as it can suppress the
NF-κB responses in mice. In colonic tumorigenesis, however, AvrA
promotes tumor growth, and we have found that NF-κB is not
persistently activated. Whether chronic infection with AvrA-
expressing bacteria contributes to suppressing NF-κB despite
promoting tumorigenesis will require further study.
A study revealed that myeloid differentiation primary response
gene 88 (MyD88) mediates microbe-induced TLR signaling and
regulates Myc oncogene expression and related IEC tumor growth in
a susceptible host [33]. We did not see MYD88 protein differences,
indicating that the effects of AvrA were not mediated by changes in
MYD88 expression (data not shown). MyD88-independent activation of
ERK by epidermal growth factor increased p-ERK and c-Myc and restored
the multiple intestinal neoplasia (Min) phenotype in Apc(min/+)/
Myd88(−/−) mice. However, we did not find that AvrA modulated
activation of ERK in the infected mice (data not shown). We did not
examine Salmonella-infected Apc mutant min mice because these mice
have constitutive β-catenin activation arising from Apc loss.
Wnt/β-catenin and STAT3 are known to cross-talk to maintain
murine embryonic stem cells in an undifferentiated state [34].
STAT3 promoter possesses a β-catenin/Tcf cis-acting element in
human cells and is upregulated by Wnt signaling in esophageal
cancers [35]. Conversely, STAT3 binds β-catenin promoters and
activates β-catenin transcription in human breast cancer cells [36].
We have found that AvrA induces both β-catenin and STAT3 signals,
which could be through deubiquitination [17]. But further studies
will be needed to determine the more proximal target in vivo.
In summary, this study reveals a novel mechanism linking bacterial
AvrA protein to host oncogenic signals that promote colon cancerdevelopment (Figure 5). Salmonella effector AvrA persistently upregu-
lates the STAT-3 signaling pathway. We further identified several
STAT3 target genes that were upregulated by Salmonella expressing
AvrA, predicted to promote proliferation and intestinal tumorigenesis
(Figure 5). Our previous study showed the role of β-catenin in chronic
Salmonella infection and differences between AvrA− and AvrA+ AOM/
DSS experimental groups in tumor development [19]. β-catenin–
STAT3 may co-regulate one another in a positive feedback loop
(Figure 5). Thus, our results bring us one step closer to unraveling
infection-related dysregulation of host signaling in cancer. Signaling
pathways, which connect infection, inflammation, and cancer,
moreover, have emerged as attractive targets for prevention and
therapy. These insights might suggest future biomarkers to risk
assessment and early detection of infection-related cancer.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes ofHealth.The protocolwas approved by theUniversity
of Rochester University Committee on Animal Resources committee
(UCAR 2007-065). All efforts were made to minimize suffering.
Bacterial Strains and Growth Condition
Bacterial strains used in this study included Salmonella mutant
strains PhoPc [28], PhoPcAvrA−, and PhoPcAvrA−/AvrA+. Non-
agitated microaerophilic bacterial cultures were prepared by inocu-
lating 10 ml of Luria-Bertani broth with 0.01 ml of stationary-phase
culture followed by overnight incubation (~18 hours) at 37°C, as
previously described [16].
Table 1. Primers for real-time PCR.
Name Sequence (5' −N 3')
Mmp7 Forward CTGCCACTGTCCCAGGAAG
Reverse GGGAGAGTTTTCCAGTCATGG
mmp9 Forward CTGGACAGCCAGACACTAAAG
Reverse CTCGCGGCAAGTCTTCAGAG
TNF alpha Forward CCCTCACACTCAGATCATCTTCT
Reverse GCTACGACGTGGGCTACAG
KC(CXCL1) Forward CTGGGATTCACCTCAAGAACATC
Reverse CAGGGTCAAGGCAAGCCTC
IL17 Forward AGCACACCCGTCTTCTCTC
Reverse GCTGGAGTTCGCACTGTCC
MIP2 Forward GAACAAAGGCAAGGCTAACTGA
Reverse AACATAACAACATCTGGGCAAT
ICAM Forward TGTGCTTTGAGAACTGTGGCA
Reverse TGGCGGCTCAGTATCTCCTC
IL 1β Forward GCAACTGTTCCTGAACTCAACT
Reverse ATCTTTTGGGGTCCGTCAACT
JAK2 Forward GGAATGGCCTGCCTTACAATG
Reverse TGGCTCTATCTGCTTCACAGAAT
STAT1 Forward TCACAGTGGTTCGAGCTTCAG
Reverse CGAGACATCATAGGCAGCGTG
STAT3 Forward CACCTTGGATTGAGAGTCAAGAC
Reverse AGGAATCGGCTATATTGCTGGT
Socs3 Forward TGCGCCTCAAGACCTTCAG
Reverse GCTCCAGTAGAATCCGCTCTC
Actin Forward TGTTACCAACTGGGACGACA
Reverse CTGGGTCATCTTTTCACGGT
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Animal experiments were performed by using specific pathogen-
free female C57BL/6 mice (Taconic) that were 6 to 7 weeks old, as
previously described [27]. Water and food were withdrawn 4 hours
before oral gavage with 7.5 mg/mouse of streptomycin (100 μl of
sterile solution). Afterward, animals were supplied with water and
food ad libitum. Twenty hours after streptomycin treatment, water
and food were withdrawn again for 4 hours before the mice were
infected with 1 × 106 CFU of S. typhimurium (100-μl suspension in
Hank’s balanced salt solution) or treated with sterile Hank’s balanced
salt solution (control) by oral gavage, as previously described [25].
After Salmonella gavage, the mice were injected with 10 mg/kg body
weight of AOM (Sigma-Aldrich) by intraperitoneal injection as
described by Greten and colleagues [37]. After a 7-day recovery
period, the animals were started on the first of four cycles of 1% DSS
ad libitum [19]. Sixteen week later, mice received second AOM
injection and another three cycles of 1% DSS in the drinking water.
At 1, 15, 25, 35, and 45 weeks after Salmonella gavage, tissue samples
were collected. For tumor enumeration and tumor dimensions,
investigators were blinded to treatment conditions and used a
stereodissecting microscope. Severity of inflammation and dysplasia
were scored by a gastrointestinal pathologist (Z. Z.) blinded to
treatment conditions using (hematoxylin and eosin) stained micro-
scopic sections [38] from colons prepared as Swiss rolls. Histologic
inflammatory scores were determined using a previously validated
scoring system [39]. Histologic assessment of intestinal tumors in
rodents was performed following recommended guidelines [40] as
recently reported by our laboratory [19].
Histological Testing
Tissues were fixed in 10% neutral buffered formaldehyde for 4 to 12
hours, transferred into 70% ethanol, and processed by standard
techniques. Sections (5 μm) were stained with hematoxylin and eosin.
For immunostaining, antigens were retrieved by boiling for 10minutes in
10 mM citrate (pH 6.0). Immunohistochemistry was done as previouslydescribed [17,41]. The slides were stained with anti–pho-c-Jun, anti–
pho-stat3, anti-stat3 (Cell Signal, Beverly, MA), anti-PCNA, anti-CD3,
and anti-CD11b (Santa Cruz Biotechnology Inc., CA) antibodies.
Immunoblotting
Mouse intestinal mucosa, including most proximal and distal
regions, was collected by scraping as previously described [27]. Mouse
epithelial cells were broken in a lysis buffer (1% Triton X-100, 150
mM NaCl, 10 mM Tris pH 7.4, 1 mM EDTA, 1 mM EGTA pH
8.0, 0.2 mM sodium orthovanadate, and protease inhibitor cocktail)
(Roche, Nutley, NJ). Immunoblotting was performed with primary
antibodies: anti–phospho-Stat1, anti–phospho-Stat3, anti–phospho-
Jak2, anti-Stat1, anti-Stat3, and anti-Jak2 (Cell Signal, Beverly, MA),
or anti–beta-actin (Sigma-Aldrich, Milwaukee, WI) antibodies and
secondary antibodies visualized by ECL [42].
Immunofluorescence
Intestinal tissues were freshly isolated and embedded in paraffin
wax after fixation with a 10% neutral buffered formalin. Immuno-
histochemistry was performed on paraffin-embedded sections (4 μm)
of mouse colons. After preparation of the slides as described
previously [17], slides were incubated in 3% hydrogen peroxide for
20 minutes at room temperature to block endogenous peroxidase
activity, followed by incubation for 20 minutes in 5% BSA with 0.1%
saponin in PBS to reduce nonspecific background. The slides were
stained with primary antibodies to CD4, CD14, or CD45 (Santa
Cruz Biotechnology Inc., Santa Cruz, CA). Specimens were
examined with a Leica SP5 Laser Scanning confocal microscope.
Real-Time Quantitative PCR Analysis
The total RNA from intestinal mucosa was extracted for a real-time
PCR 45 weeks postinfection using TRIzol reagent (Invitrogen, Grand
Island, NY). The RNA integrity was verified by electrophoresis. RNA
reverse transcription was performed using the iScript cDNA synthesis
kit (Bio-Rad, Hercules, CA) according to the manufacturer's
protocol. The RT cDNA reaction products were subjected to
quantitative real-time PCR using CTFX 96 Real-Time System
(Bio-Rad, Hercules, CA) and SYBR Green Supermix (Bio-Rad)
according to the manufacturer's protocol. All expression levels were
normalized to β-actin levels of the same sample. Percent expression
was calculated as the ratio of the normalized value of each sample to
that of the corresponding untreated control cells. All real-time PCRs
were performed in triplicate. Optimal primer sequences were
designed using Primer-BLAST or were obtained from Primer Bank
primer pairs listed in Table 1.
Transfection and Luciferase Assay for STAT3 Transcriptional
Activity
HCT1116 human colon cancer cells were transiently co-transfected
with pGL3-STAT3&pCMV-AvrA or pGL3-Basic&pCMV-AvrA
using lipofectin reagent according to the manufacturer’s instructions
(Invitrogen, CA). PRL-TK vector was used as an internal control
reporter. Luciferase activity was monitored using the dual luciferase
assay system (Promega, Madison, WI). Experiments were done in
triplicate with three repeats.
Statistical Analysis
Data are expressed as mean ± SD. All statistical tests were
two-sided. P values of less than .05 were considered to be statistically
significant. For cecum data, four areas of mouse body were checked to
Neoplasia Vol. 18, No. 5, 2016 Bacterial Protein and STAT3 in Colon Cancer Lu et al. 315obtain the average infection score. Then, multiple comparisons of
mean infection score were performed using analysis of variance.
Following analysis of overall group differences on the mean scores at
P ≤ .05, alpha levels were adjusted using the Tukey correction for
multiple comparisons. As the study involved a longitudinal design,
the generalized estimating equations were utilized to provide
statistical inference [43]. The analysis was conducted using the
Genmod procedure in SAS. The overall treatment effects were
modeled using the time by treatment interaction term through intake
(week 0) to week 45 [25]. Statistical analyses were performed using
SAS version 9.2 (SAS Institute, Inc., Cary, NC).
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